Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

- PMLiVE

EMA and FDA calls for innovative approaches for Gaucher disease medicines

The regulatory agencies also urge a similar method for all paediatric diseases

- PMLiVE

Your doctor has no time to see you now

Changing the way HCPs connect with each other to positively impact the fraying patient-doctor relationship

- PMLiVE

FDA moves to tackle orphan designation backlog

Some 200 requests are awaiting review by the US regulator

- PMLiVE

GSK signs up to apply AI to drug discovery

Will work with Exscientia on 10 small molecule targets

GSK signs up to apply AI to drug discovery

Will work with Exscientia on 10 small molecule targets

Internships: Growing the pool of recruitable talent, or cheap labour?

How 'try before you buy' can be an enormous help in medical communications

What makes the difference in the biosimilar battle?

The biosimilar market is set to get competitive but only players with a clear differentiation will succeed

National Institute for Health and Care Excellence NICE logo

NICE backs Lilly’s rheumatoid arthritis drug Olumiant

The drug will be used alongside methotrexate to treat adults with severe, active RA

Loss aversion

Healthcare's most important behavioural lesson

Daiichi Sankyo logo

Daiichi drug hits mark in shingles pain, but misses in other indications

ALDAY trial shows mirogabalin was unable to reduce pain for fibromyalgia patients

Lucid Partners grows its medical writing team

The past year has been the most successful for Lucid Group yet. They have celebrated their 10th year of business, launched their new Strategic Consultancy, won a Queen’s Award for...

Lucid Group Communications Limited

- PMLiVE

The Communiqué Awards at 20: Dennis O’Brien

Lucid's CEO on the Awards' enduring influence

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links